Evidence map›Paper›PMID 30171024›Full record

Trial reportHaematologica2019

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Sylvain Carras, Emmanuelle Tchernonog, Anna Schmitt, Roch Houot, Caroline Dartigeas, Jean Michel Pignon and 31 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Molecular profiling and management of mantle cell lymphoma.Hematology. American Society of Hematology. Education Program · 2019
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 20 institutions in 1 country.

Rémy GressinOnco-Hematology Department, Grenoble University Hospital rgressin@chu-grenoble.fr mary.callanan@chu-dijon.fr.
Nicolas DaguindauHematology Department, Annecy Hospital.
Adrian TempesculHematology Department, Brest University Hospital.
Anne MoreauPathology Department, Nantes University Hospital.
Sylvain CarrasOnco-Hematology Department, Grenoble University Hospital.
Emmanuelle TchernonogHematology Department, Montpellier University Hospital.
Anna SchmittHematology Department, Cancer Institute Bergonie Bordeaux.
Roch HouotHematology Department, Rennes University Hospital.
Caroline DartigeasHematology Department, Tours University Hospital.
Jean Michel PignonHematology Department, Dunkerque Hospital.
Selim CormHematology Department, Chambery Hospital.
Anne BanosHematology Department, Bayonne Hospital.
Christiane MounierHematology Department, Loire Cancer Institute, Saint Etienne.
Jehan DupuisLymphoid Malignancies Unit, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil.
Margaret MacroIHBN - Hematology Department, Caen University Hospital.
Joel FleuryHematology Department, Clermont-Ferrand Cancer Institute.
Fabrice JardinHematology Department, Rouen University Hospital.
Clementine SarkozyHematology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud. INSERM 1052.
Ghandi DamajHematology Department, Amiens University Hospital.
Pierre FeugierHematology Department, Nancy University Hospital.
Luc Matthieu ForneckerHematology Department, University Hospital Strasbourg.
Cecile ChabrotHematology Department, University Clermont-Ferrand Hospital.
Veronique DorvauxHematology Department, Metz University Hospital.
Krimo BouadallahHematology Department, Bordeaux University Hospital.
Sandy AmorinHematology Department, University Hospital Paris Saint-Louis.
Reda GaridiHematology Department, Saint Quentin Hospital.
Laurent VoillatHematology Department, Chalon Hospital.
Bertrand JolyHematology Department, Corbeil Hospital.
Philippe Solal CelignyHematology Department, Victor Hugo Clinic, Le Mans.
Nadine MorineauHematology Department, Catherine de Sienne Clinic, Nantes.
Marie Pierre MolesHematology Department, Angers University Hospital.
Hacene ZerazhiHematology Department, Avignon Hospital.
Jean FontanHematology Department, Besançon University Hospital.
Yazid ArkamHematology Department, Mulhouse Hospital.
Magda AlexisHematology Department, Orleans Hospital.
Vincent DelwailOnco-Hematology Department, University Hospital Poitiers and INSERM, CIC 1402, Poitiers University.
Jean Pierre VilqueHematology Department, Baclesse Caen Cancer Center.
Loic YsebaertHematology Department, Toulouse University Hospital.
Steven Le GouillHematology Department, Nantes University Hospital.
Mary B CallananINSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble-Alpes, Institute for Advanced Biosciences, Grenoble rgressin@chu-grenoble.fr mary.callanan@chu-dijon.fr.
Lymphoma Study Association
Centre Hospitalier Universitaire de Clermont-Ferrand · FRCentre National de la Recherche Scientifique · FRCentre François Baclesse · FRCentre Hospitalier de la Côte Basque · FRCentre Hospitalier de Mulhouse · FRCentre Hospitalier de Saint-Quentin · FRCentre Hospitalier Métropole Savoie · FRCentre Hospitalier Régional de Metz-Thionville · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier Sud Francilien · FRCentre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Caen Normandie · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Poitiers · FRCentre Hospitalier Universitaire de Rouen · FRCentre Hospitalier Universitaire de Saint-Étienne · FRCentre Hospitalier Universitaire de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrolled (median age, 73 years). Patients received a maximum of six cycles of treatment at 28-day intervals. The primary objective was to achieve an 18-month progression-free survival rate of 65% or higher. Secondary objectives were to evaluate toxicity and the prognostic impact of mantle cell lymphoma prognostic index, Ki67 expression, [

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBortezomibDexamethasoneDisease-Free SurvivalFemaleHumansLymphoma, Mantle-CellMaleMiddle AgedRituximabSurvival RateTime FactorsBendamustine HydrochlorideBortezomibDexamethasoneRituximab

Identifiers

PMID30171024
PMCPMC6312036
OpenAlexW2889531115

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.